Form 8-K - Current report:
SEC Accession No. 0001157523-23-000343
Filing Date
2023-02-23
Accepted
2023-02-23 08:00:37
Documents
13
Period of Report
2023-02-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 EDGEWISE THERAPEUTICS, INC. 8-K a53339740.htm   iXBRL 8-K 28264
2 EXHIBIT 99.1 a53339740_ex991.htm EX-99.1 61189
  Complete submission text file 0001157523-23-000343.txt   239086

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20230223.xsd EX-101.SCH 3929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20230223_lab.xml EX-101.LAB 23288
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20230223_pre.xml EX-101.PRE 16554
7 EXTRACTED XBRL INSTANCE DOCUMENT a53339740_htm.xml XML 4225
Mailing Address 3415 COLORADO AVE. BOULDER CO 80303
Business Address 3415 COLORADO AVE. BOULDER CO 80303 303-735-8373
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 23656000
SIC: 2834 Pharmaceutical Preparations